PMID- 31536546
OWN - NLM
STAT- MEDLINE
DCOM- 20200306
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 9
DP  - 2019
TI  - Clinical factors associated with bacterial translocation in Japanese patients 
      with type 2 diabetes: A retrospective study.
PG  - e0222598
LID - 10.1371/journal.pone.0222598 [doi]
LID - e0222598
AB  - OBJECTIVE: To explore clinical factors associated with bacterial translocation in 
      Japanese patients with type 2 diabetes mellitus (T2DM). METHODS: The data of 118 
      patients with T2DM were obtained from two previous clinical studies, and were 
      retrospectively analyzed regarding the clinical parameters associated with 
      bacterial translocation defined as detection of bacteremia and levels of plasma 
      lipopolysaccharide binding protein (LBP), the latter of which is thought to 
      reflect inflammation caused by endotoxemia. RESULTS: LBP level was not 
      significantly different between patients with and without bacteremia. No clinical 
      factors were significantly correlated with the detection of bacteremia. On the 
      other hand, plasma LBP level was significantly correlated with HbA1c (r = 0.312), 
      fasting blood glucose (r = 0.279), fasting C-peptide (r = 0.265), body mass index 
      (r = 0.371), high-density lipoprotein cholesterol (r = -0.241), and inflammatory 
      markers (high-sensitivity C-reactive protein, r = 0.543; and interleukin-6, r = 
      0.456). Multiple regression analysis identified body mass index, HbA1c, 
      high-sensitivity C-reactive protein, and interleukin-6 as independent 
      determinants of plasma LBP level. CONCLUSION: The plasma LBP level was similar in 
      patients with and without bacteremia. While both bacteremia and LBP are 
      theoretically associated with bacterial translocation, the detection of 
      bacteremia was not associated with LBP level in T2DM.
FAU - Tamaki, Shoko
AU  - Tamaki S
AD  - Department of Metabolism & Endocrinology, Juntendo University Graduate School of 
      Medicine, Tokyo, Japan.
FAU - Kanazawa, Akio
AU  - Kanazawa A
AUID- ORCID: 0000-0003-2292-395X
AD  - Department of Metabolism & Endocrinology, Juntendo University Graduate School of 
      Medicine, Tokyo, Japan.
FAU - Sato, Junko
AU  - Sato J
AD  - Department of Metabolism & Endocrinology, Juntendo University Graduate School of 
      Medicine, Tokyo, Japan.
FAU - Tamura, Yoshifumi
AU  - Tamura Y
AD  - Department of Metabolism & Endocrinology, Juntendo University Graduate School of 
      Medicine, Tokyo, Japan.
AD  - Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
FAU - Asahara, Takashi
AU  - Asahara T
AD  - Probiotics Research Laboratory, Juntendo University Graduate School of Medicine, 
      Tokyo, Japan.
AD  - Yakult Central Institute, Tokyo, Japan.
FAU - Takahashi, Takuya
AU  - Takahashi T
AD  - Probiotics Research Laboratory, Juntendo University Graduate School of Medicine, 
      Tokyo, Japan.
AD  - Yakult Central Institute, Tokyo, Japan.
FAU - Matsumoto, Satoshi
AU  - Matsumoto S
AD  - Probiotics Research Laboratory, Juntendo University Graduate School of Medicine, 
      Tokyo, Japan.
AD  - Yakult Central Institute, Tokyo, Japan.
FAU - Yamashiro, Yuichiro
AU  - Yamashiro Y
AD  - Probiotics Research Laboratory, Juntendo University Graduate School of Medicine, 
      Tokyo, Japan.
FAU - Watada, Hirotaka
AU  - Watada H
AD  - Department of Metabolism & Endocrinology, Juntendo University Graduate School of 
      Medicine, Tokyo, Japan.
AD  - Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
AD  - Center for Therapeutic Innovations in Diabetes, Juntendo University Graduate 
      School of Medicine, Tokyo, Japan.
AD  - Center for Identification of Diabetic Therapeutic Targets, Juntendo University 
      Graduate School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190919
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Acute-Phase Proteins)
RN  - 0 (Biomarkers)
RN  - 0 (C-Peptide)
RN  - 0 (Carrier Proteins)
RN  - 0 (Interleukin-6)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (lipopolysaccharide-binding protein)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Acute-Phase Proteins
MH  - Asian People
MH  - Bacterial Translocation/*physiology
MH  - Biomarkers/blood
MH  - C-Peptide/blood
MH  - C-Reactive Protein/metabolism
MH  - Carrier Proteins/blood
MH  - Diabetes Mellitus, Type 2/blood/metabolism/*microbiology
MH  - Endotoxemia/blood/metabolism/microbiology
MH  - Female
MH  - Humans
MH  - Inflammation/blood/metabolism/microbiology
MH  - Interleukin-6/blood
MH  - Male
MH  - Membrane Glycoproteins/blood
MH  - Middle Aged
MH  - Retrospective Studies
PMC - PMC6752875
COIS- AK has received lecture fees from Kissei Pharma, Sanofi, and Takeda 
      Pharmaceutical Company. JS has received lecture fees from Novartis 
      Pharmaceuticals, Novo Nordisk Pharma, Sanofi, and Takeda Pharmaceutical Company. 
      YT has received lecture fees from Takeda Pharmaceutical Company, MSD, Eli Lilly, 
      Kissei Pharma, and AstraZeneca. HW has received lecture fees from Novo Nordisk, 
      Inc., Eli Lilly and Company, Sanofi, Dainippon Sumitomo Pharma Co., Fujifilm, 
      Bayer Health Care, Kissei Pharmaceutical Company, Mochida Pharmaceutical Company, 
      MSD, Takeda Pharmaceutical Company, Boehringer Ingelheim Pharmaceuticals, Inc., 
      Daiichi-Sankyo, Ono Pharmaceutical Co., Ltd., Novartis Pharmaceuticals 
      Corporation, Mitsubishi Tanabe Pharma Corporation, AstraZeneca LP, Kyowa Hakko 
      Kirin Company, Ltd., Sanwa Kagaku Kenkyusho Company, Ltd., Kowa Company Ltd., and 
      Astellas Pharma, Inc.; advisory fees from Novo Nordisk, Inc., Mochida Pharma 
      Company, AstraZeneca LP, Kowa Company, Astellas Pharma, Inc., Sanofi, Boehringer 
      Ingelheim Pharmaceuticals, Inc., MSD, Mitsubishi Tanabe Pharma Corporation, 
      Novartis Pharmaceuticals Corporation, Dainippon Sumitomo Pharma Co., Takeda 
      Pharmaceutical Company, Ono Pharmaceutical Co., Pfizer, Inc., and Kowa Company; 
      and research funds from Boehringer Ingelheim, Pfizer, Mochida Pharmaceutical Co., 
      Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Sanwakagaku 
      Kenkyusho, Terumo Corp., Eli Lilly, Mitsubishi Tanabe Pharma, Daiichi Sankyo 
      Inc., Takeda Pharmaceutical Co., MSD, Shionogi, Pharma, Dainippon Sumitomo 
      Pharma, Kissei Pharma, and Astrazeneca., TA, TT, and SM are employed by the 
      Yakult Central Institute. ST and YY have nothing to declare. This does not alter 
      our adherence to PLOS ONE policies on sharing data and materials.
EDAT- 2019/09/20 06:00
MHDA- 2020/03/07 06:00
PMCR- 2019/09/19
CRDT- 2019/09/20 06:00
PHST- 2019/03/17 00:00 [received]
PHST- 2019/09/02 00:00 [accepted]
PHST- 2019/09/20 06:00 [entrez]
PHST- 2019/09/20 06:00 [pubmed]
PHST- 2020/03/07 06:00 [medline]
PHST- 2019/09/19 00:00 [pmc-release]
AID - PONE-D-19-07704 [pii]
AID - 10.1371/journal.pone.0222598 [doi]
PST - epublish
SO  - PLoS One. 2019 Sep 19;14(9):e0222598. doi: 10.1371/journal.pone.0222598. 
      eCollection 2019.